Stockreport

Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Quince Therapeutics, Inc.  (QNCX) 
PDF Pivotal Phase 3 NEAT clinical trial evaluating lead asset, eDSP, for the treatment of A-T remains on track with topline results expected in first quarter of 2026 SOUT [Read more]